Breaking News Instant updates and real-time market news.

Amicus to host conference call

Conference call to discuss the top-line Phase 3 ESSENCE study results will be held on September 13 at 8:30 am. Webcast Link

13

Sep

FOLDAmicus

$13.28

-0.39 (-2.85%)

06/05/17

JPMS

06/05/17NO CHANGETarget $13JPMSOverweight

Amicus shares can double on positive zorblisa data, says JPMorgan

JPMorgan analyst Anupam Rama believes investor sentiment remains very low on Amicus Therapeutics' Phase 3 readout of zorblisa. The Phase 3 Essence data for the treatment of epidermolysis bullosa are expected in Q3. The trial is "high-risk/high-reward," Rama tells investors in a research note. The analyst says he's taking a "very conservative" approach for zorblisa with $300M in peak sales and a 40% probability of success. Rama believes the stock at current levels reflects no value for zorblisa. On positive data, Amicus shares have the potential to double, Rama writes. On negative data, he sees only "sentiment based" downside of 5%-15%. The analyst keeps an Overweight rating on Amicus with a $13 price target.

07/11/17

JPMS

07/11/17NO CHANGEJPMSOverweight

Amicus could be up 15%-20% on today's news, says JPMorgan

JPMorgan analyst Anupam Rama believes shares of Amicus Therapeutics could be up 15%-20% today on news of the FDA confirming that the regulatory filing for migalastat for the treatment of Fabry can now be submitted. The stock in premarket trading is up 31% to $13.45. The analyst estimates that a U.S. launch of migalastat is now moved up by two years. Rama has an Overweight rating on Amicus.

07/11/17

COWN

07/11/17NO CHANGETarget $16COWNOutperform

Amicus price target raised to $16 from $10 at Cowen

08/17/17

JPMS

08/17/17NO CHANGEJPMS

JPMorgan lists top SMID Biotechnology picks following Q2 results

Analysts at JPMorgan continue think selectively remains important in the small-to-mid cap Biotechnology space. The analysts listed their favorite ideas in "five key buckets." Amicus (FOLD) is the top long-term pick, Ironwood (IRWD) is the top pick among relative underperformers, Otonomy (OTIC) is the top play for a clinical/binary event, Sarepta (SRPT) is the name to take advantage of the recent share weakness, and Ignyta (RXDX) is the "underfollowed/undervalued" favorite, according to JPMorgan's Biotech team.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.